Medtronic Adds Heart Devices in $1.1 Billion HeartWare Deal

  • Premium of 93% compared with HeartWave closing price Friday
  • Biggest acquisition since 2015 purchase of Dublin’s Covidien

A worker inspects a membrane that will be used in the production of human heart valve replacements at the Medtronic assembly plant in Tijuana, Mexico.

Photographer: David Maung/Bloomberg
Lock
This article is for subscribers only.

Medtronic Plc, the world’s biggest maker of heart-rhythm devices, agreed to buy HeartWare International Inc. for about $1.1 billion, paying a premium of 93 percent to gain an implanted device that takes over the pumping action for a failing heart.

Medtronic will pay $58 a share, according to a statementBloomberg Terminal Monday, almost double HeartWare’s Friday closing price of $29.98. The offer trails HeartWare’s 12-month high of $90.71, reached in July. The company has faced setbacks in the development of its newest pump, and in January said it was abandoning an attempt to buy Valtech Cardio Ltd. -- a deal opposed by some investors.